Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients

Haematologica

Volumn 84, Issue 11, 1999, Pages 1016-1023

  Palmeri, Sergio ^b   Leonardi, Vita ^c   Danova, Marco ^c   Porta, Camillo ^c   Ferrari, Silvia ^c   Fincato, Gianluca ^a   Citarrella, Pietro ^c  

^a Novartis Pharma   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NONE

Author keywords

Chemotherapyinduced myelosuppression; G CSF; GM CSF; Interleukin 3

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 3; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE; VINCA ALKALOID;

ARTICLE; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE; LEUKOPENIA; MALE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PLATELET COUNT; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032714317     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vose MJ, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995; 13:1023-35.
2. Antmann KS, Griffin JD, Elias A, et al. Effect of recombinant human GM-CSF on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319:593-8.
3. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of G-CSF on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 319:1414-22.
4. Bronchud MH, Scarffe JH, Thathcer N, et al. Phase I/II study of recombinant human G-CSF in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56:809-13.
5. Morstyn G, Campbell L, Souza LM, et al. Effect of G-CSF on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; i:667-72.
6. Gabrilove LK, Jakubowski A, Fain K. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82:1454-61.
7. Herrmann F, Schulz G, Wieser M, et al. Effect of GM-CSF in neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 1990; 8:619-24.
8. Ohno R, Tomonaga M, Kobayashi T. Effect of G-CSF after intensive induction chemotherapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871-7.
9. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human GM-CSF on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869-76.
10. Crawford J, Ozer H, Stoller R, et al. Reduction by G-CSF of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164-70.
11. Mangi MH, Newland AC. Interleukin-3: promises and perspectives. Hematology 1993; 3:55-66.
12. Ganser A, Lindemann A, Seipelt G, et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76:666-76.
13. Lindemann A, Ganser F, Hermann F, et al. Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991; 9:2120-7.
14. Raquette RL, Zhou JY, Yang YC, et al. Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. Blood 1988; 71:1596-600.
15. Broxmeyer HE, Williams D, Hangoc G, et al. Synergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine CSF-1, recombinant murine interleukin-3, and recombinant murine GM-CSF. Proc Natl Acad Sci USA 1987; 84: 3871-5.
16. Donahue RE, Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241:1820-3.
17. Krumwieh D, Seiler FR. In vivo effects of recombinant colony stimulating factors on hematopoiesis in cynomolgus monkeys. Transplant Proc 1989; 21:2964-7.
18. Mayer P, Valent P, Schmidt G, et al. The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood 1989; 74:613-21.
19. Geissler K, Valent P, Mayer P, et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates - Synergism with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75:5-10.
20. World Health Organization. WHO Handbook for reporting results of cancer treatment. Offset publication 48. Geneva: World Health Organization, 1979.
21. Bregni M, Siena S, Di Nicola M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 1996; 14:628-35.
22. Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 6:455-62.
23. 2) cyclophosphamide cancer therapy. Ann Oncol 1993; 4:759-66.
24. Orazi A, Cattoretti G, Schirò R, et al. Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow. Blood 1992; 79:2610-9.
25. Danova M, Mazzini G, Alberici R, et al. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors: cytokinetic effects on bone marrow hematopoietic progenitors. Int J Oncol 1996; 9:971-6.
26. Stahl CP, Winton EF, Monroe MC, et al. Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates. Blood 1992; 80:2479-85.
27. Myajima A, Mui ALF, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony stimulating factor, interleukin-3 and interleukin-5. Blood 1993; 82:1960-74.
28. Taketazu F, Chiba S, Shibuya K, et al. IL-3 specifically inhibits GM-CSF binding to the higher affinity receptor. J Cell Physiol 1991; 146:251-7.
29. Farese AM, Williams DE, Seiler F, et al. Combination protocols of cytokine therapy with interleukin-3 and granulocyte colony-stimulating factor in a primate model of radiation induced marrow aplasia. Blood 1993; 82:3112-8.
30. Van Gils FCJM, Budel LM, Burger H, et al. Interleukin-3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of IL-3, binding characteristics, and lack of competition with GM-CSF. Exp Hematol 1994; 22:248-55.
31. Ballestrero A, Ferrando F, Garuti A, et al. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. J Clin Oncol 1999; 17:1296-303.
32. Leonardi V, Danova M, Fincato G, Palmeri S. Interleukin-3 in the treatment of chemotherapy-induced thrombocytopema. Oncol Rep 1998; 5:1459-64.